Randomized Multicenter Study of 5 vs 6 Weekly Fraction of RT in the Treatment of SCC of the Head and Neck
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Riyadh, Saudi Arabia, 1211
- KFSH&RC
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with SCC of the head and neck
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
safety
Time Frame: 5 years
|
5 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Nasser Al Rajhi, MD, KFSH&RC
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- RAC#0981-019
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma, Squamous Cell
-
NCT01267240TerminatedRecurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Stage IVA Oral Cavity Squamous Cell Carcinoma | Stage IVA Laryngeal Squamous Cell Carcinoma | Stage IVA Oropharyngeal Squamous Cell Carcinoma | Stage IVB Laryngeal Squamous Cell Carcinoma | Stage IVB Oropharyngeal Squamous Cell Carcinoma | Stage IVC Laryngeal Squamous Cell Carcinoma
-
NCT03032250CompletedRecurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Caregiver | Salivary Gland Squamous Cell Carcinoma | Malignant Head and Neck Neoplasm | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Stage IV Hypopharyngeal Squamous Cell Carcinoma | Stage IVA Laryngeal Squamous Cell Carcinoma | Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma
-
NCT06568172SuspendedStage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8 | Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8 | Eyelid Squamous Cell Carcinoma | Skin Acantholytic Squamous Cell Carcinoma | Skin Clear Cell Squamous Cell Carcinoma | Skin Lymphoepithelial Carcinoma | Skin Spindle Cell Squamous Cell Carcinoma | Skin Squamous Cell Carcinoma With Sarcomatoid Differentiation | Recurrent Eyelid Squamous Cell Carcinoma | Recurrent Skin Acantholytic Squamous Cell Carcinoma
-
NCT05085496RecruitingLocally Advanced Skin Squamous Cell Carcinoma | Unresectable Skin Squamous Cell Carcinoma | Resectable Skin Squamous Cell Carcinoma
-
NCT05729139WithdrawnSquamous Cell Carcinoma | Cutaneous Squamous Cell Carcinoma | Advanced Squamous Cell Carcinoma
-
NCT03381183CompletedSquamous Cell Carcinoma of the Head and Neck | Oropharynx Squamous Cell Carcinoma | Squamous Cell Carcinoma | Oral Cavity Squamous Cell Carcinoma | Metastatic Squamous Cell Carcinoma | Hypopharynx Squamous Cell Carcinoma | Paranasal Sinus Squamous Cell Carcinoma | Larynx Squamous Cell Carcinoma
-
NCT07079410Not yet recruitingOropharyngeal Squamous Cell Carcinoma | Oral Squamous Cell Carcinoma (OSCC) | Resectable Oral and Oropharyngeal Squamous Cell Carcinoma
-
NCT04564989RecruitingCarcinoma, Squamous Cell | Head and Neck Squamous Cell Carcinoma | Oropharyngeal Squamous Cell Carcinoma | Oropharynx Squamous Cell Carcinoma
-
NCT04163952TerminatedMetastatic Skin Squamous Cell Carcinoma | Recurrent Skin Squamous Cell Carcinoma | Locally Advanced Skin Squamous Cell Carcinoma
-
NCT03342911CompletedStage IVA Oral Cavity Squamous Cell Carcinoma | Stage IV Hypopharyngeal Squamous Cell Carcinoma | Stage IVA Laryngeal Squamous Cell Carcinoma | Stage IVA Oropharyngeal Squamous Cell Carcinoma | Stage IVB Laryngeal Squamous Cell Carcinoma | Stage IVB Oropharyngeal Squamous Cell Carcinoma | Stage IVC Laryngeal Squamous Cell Carcinoma | Stage IVC Oropharyngeal Squamous Cell Carcinoma | Stage II Oropharyngeal Squamous Cell Carcinoma | Stage III Hypopharyngeal Squamous Cell Carcinoma
Clinical Trials on 5 vs 6 weekly fraction of RT
-
NCT02857855Active, not recruiting
-
NCT00334269Completed
-
NCT01628237Completed
-
NCT02658097Completed
-
NCT07046897RecruitingMicrobiota Analysis in Healthy Subjects
-
NCT01086826CompletedHead and Neck Squamous Cell Carcinoma
-
NCT04585217CompletedPtosis, Eyelid | Dermatochalasis
-
NCT06197581RecruitingSafety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer (RADIOCOM)Chemotherapeutic Toxicity | Radiotherapy; Complications | PARP Inhibitor | Immune Checkpoint Inhibitor | Trastuzumab | Breast Cancer, Familial Male | CDK4/6 Inhibitor | Pertuzumab